# Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Canonical URL: https://biopharmsignal.com/news/ABSI/absci-announces-positive-interim-phase-1-data-from-the-headlinetm-trial-of-abs-201-a-novel-antibody-targeting-the-prolactin-receptor-prlr
Ticker: ABSI
Company: Absci Corporation
Source: Absci Corporation
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.absci.com
## Summary

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose

## Article Body
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose
## Recent Company News
- 2026-06-25 13:46 EST — [Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors](https://biopharmsignal.com/news/ABSI/absci-announces-pricing-of-100-million-underwritten-offering-with-leading-strategic-and-financial-investors) — Source: Absci Corporation
- 2026-06-25 13:46 EST — [Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)](https://biopharmsignal.com/news/ABSI/absci-announces-positive-interim-phase-1-data-from-the-headlinetm-trial-of-abs-201-a-novel-antibody-targeting-the-prolactin-receptor-prlr) — Source: Absci Corporation
- 2026-06-25 13:46 EST — [Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-first-quarter-2026-financial-and-operating-results) — Source: Absci Corporation
- 2026-06-25 13:46 EST — [Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/ABSI/absci-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference) — Source: Absci Corporation
- 2026-06-25 13:46 EST — [Absci to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ABSI/absci-to-participate-in-upcoming-investor-conferences) — Source: Absci Corporation
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)